Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223221 | 1.00 | ACACB (0.38) | ACACBSLC6A4CHEK1FASNCYP2C9 | |
| SCHEMBL2860558 | 0.83 | KDM4E (0.39) | ACACBCHEK1FASN | |
| SCHEMBL29989 | 0.81 | ACACB (0.38) | ACACBCHEK1FASNCYP2C9S1PR1 | |
| SCHEMBL18721893 | 0.79 | ESR2 (0.44) | ACACBCHEK1FASNCYP2C9HRH3 | |
| SCHEMBL13674322 | 0.78 | SLC6A4 (0.50) | SLC6A4FASNCYP2C9HRH3SPHK1 | |
| SCHEMBL22047801 | 0.76 | CHEK1 (0.40) | ACACBCHEK1FASNSPHK1 | |
| SCHEMBL10000790 | 0.76 | MAPT (0.39) | ACACBCYP2C9SPHK1 | |
| SCHEMBL14045979 | 0.76 | KDM4E (0.50) | CHEK1FASNHRH3 | |
| SCHEMBL16349362 | 0.75 | MAPT (0.40) | ACACBCYP2C9SPHK1 | |
| SCHEMBL3237238 | 0.72 | ESR2 (0.46) | ACACBCHEK1FASNCYP2C9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-1904435-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. | 2010-03-18 | — | — | US | disclosed |
| US-7605289-B2 | Benzamide derivatives and uses related thereto | AMGEN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605289-B2 | Benzamide derivatives and uses related thereto | AMGEN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | AMGEN INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | GPR119, GLP1R, UGT2B7 | ACACB 1067/4885SLC6A4 1961/4885CHEK1 3861/4885 |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | GPR119, GLP1R, UGT2B7 | ACACB 1067/4885SLC6A4 1961/4885CHEK1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.